🚀 VC round data is live in beta, check it out!
Eurofins-Cerep Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eurofins-Cerep and similar public comparables like Fractyl Health, Inovio Pharmaceuticals, Allianca Saude, Q32 Bio and more.
Eurofins-Cerep Overview
About Eurofins-Cerep
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
Founded
1989
HQ
Employees
146
Website
Financials (FY)
EV
$78M
Eurofins-Cerep Financials
Eurofins-Cerep reported last fiscal year revenue of $48M and EBITDA of $10M.
In the same fiscal year, Eurofins-Cerep generated $20M in gross profit, $10M in EBITDA, and $8M in net income.
Eurofins-Cerep P&L
In the most recent fiscal year, Eurofins-Cerep reported revenue of $48M and EBITDA of $10M.
Eurofins-Cerep expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $48M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 43% | XXX | XXX | XXX |
| EBITDA | — | XXX | $10M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | $8M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eurofins-Cerep Stock Performance
Eurofins-Cerep has current market cap of $94M, and enterprise value of $78M.
Market Cap Evolution
Eurofins-Cerep's stock price is $18,551.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $94M | -0.4% | XXX | XXX | XXX | $1,665.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEurofins-Cerep Valuation Multiples
Eurofins-Cerep trades at 1.6x EV/Revenue multiple, and 7.4x EV/EBITDA.
Eurofins-Cerep Financial Valuation Multiples
As of April 22, 2026, Eurofins-Cerep has market cap of $94M and EV of $78M.
Equity research analysts estimate Eurofins-Cerep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eurofins-Cerep has a P/E ratio of 11.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94M | XXX | $94M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.8x | XXX | XXX | XXX |
| P/E | — | XXX | 11.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eurofins-Cerep Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eurofins-Cerep Margins & Growth Rates
Eurofins-Cerep's revenue in the last fiscal year declined by (8%).
Eurofins-Cerep's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Eurofins-Cerep Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (8%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (2%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eurofins-Cerep Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eurofins-Cerep | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Inovio Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Allianca Saude | XXX | XXX | XXX | XXX | XXX | XXX |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| AB Science | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eurofins-Cerep M&A Activity
Eurofins-Cerep acquired XXX companies to date.
Last acquisition by Eurofins-Cerep was on XXXXXXXX, XXXXX. Eurofins-Cerep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eurofins-Cerep
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEurofins-Cerep Investment Activity
Eurofins-Cerep invested in XXX companies to date.
Eurofins-Cerep made its latest investment on XXXXXXXX, XXXXX. Eurofins-Cerep invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eurofins-Cerep
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eurofins-Cerep
| When was Eurofins-Cerep founded? | Eurofins-Cerep was founded in 1989. |
| Where is Eurofins-Cerep headquartered? | Eurofins-Cerep is headquartered in France. |
| How many employees does Eurofins-Cerep have? | As of today, Eurofins-Cerep has over 146 employees. |
| Is Eurofins-Cerep publicly listed? | Yes, Eurofins-Cerep is a public company listed on Munich Stock Exchange. |
| What is the stock symbol of Eurofins-Cerep? | Eurofins-Cerep trades under ZEP2 ticker. |
| When did Eurofins-Cerep go public? | Eurofins-Cerep went public in 2010. |
| Who are competitors of Eurofins-Cerep? | Eurofins-Cerep main competitors are Fractyl Health, Inovio Pharmaceuticals, Allianca Saude, Q32 Bio. |
| What is the current market cap of Eurofins-Cerep? | Eurofins-Cerep's current market cap is $94M. |
| What is the current revenue of Eurofins-Cerep? | Eurofins-Cerep's last fiscal year revenue is $48M. |
| What is the current EV/Revenue multiple of Eurofins-Cerep? | Current revenue multiple of Eurofins-Cerep is 1.6x. |
| Is Eurofins-Cerep profitable? | No, Eurofins-Cerep is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.